Neogen (Neogen) Change In Working Capital : $-22.7 Mil (TTM As of Feb. 2024)

View and export this data going back to 1989. Start your Free Trial

What is Neogen Change In Working Capital?

Neogen's change in working capital for the quarter that ended in Feb. 2024 was $-61.2 Mil.

Neogen's change in working capital for the fiscal year that ended in May. 2023 was $-22.8 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Neogen Change In Working Capital Historical Data

The historical data trend for Neogen's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neogen Change In Working Capital Chart

Neogen Annual Data

Trend

May14

May15

May16

May17

May18

May19

May20

May21

May22

May23

Change In Working Capital

Get a 7-Day Free Trial

-20.70

-0.06

-6.63

-6.42

-22.79

Neogen Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
Change In Working Capital	Get a 7-Day Free Trial															-56.89	65.87	-11.72	-15.57	-61.23

Neogen Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-22.7 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Neogen Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Neogen's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Neogen (Neogen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Neogen Corp (NAS:NEOG) » Definitions » Change In Working Capital

Comparable Companies

SHC RDNT GH NEO TWST MYGN VCYT OPK LAB FLGT TSE:2309 TMO DHR IQV IDXX XSWX:LONN A MTD ICLR ILMN

Traded in Other Exchanges

NG2:Germany NG2:Germany

Address

620 Lesher Place, Lansing, MI, USA, 48912

Website

https://www.neogen.com

Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety (70% of post-merger sales), Neogen performs diagnostics to detect unintended substances in food and animal feed, such as pathogens, allergens, and drug residues, for food and feed processing companies. In animal safety (20% of post-merger sales), Neogen sells veterinary instruments, pharmaceuticals, disinfectants, and genomics tests for animals, including cattle, horses, and canines. Sales in the United States account for 60% of total revenue, while international markets, including Canada, Europe, Asia, and Latin America, account for the remaining 40%.

Executives

William T Boehm	director
Douglas Edward Jones	officer: Vice President, CCO	620 LESHER PLACE, LANSING MI 48912
Jason Warren Lilly	officer: Vice President	620 LESHER PLACE, LANSING MI 48912
James P Tobin	director	620 LESHER PLACE, LANSING MI 48895
David H. Naemura	officer: VP & CFO	C/O GATES INDUSTRIAL CORPORATION PLC, 1144 FIFTEENTH STREET, SUITE 1400, DENVER CO 80202
Amy M Rocklin	officer: Chief Legal & Reg. Officer	620 LESHER PLACE, LANSING MI 48912
Steven J. Quinlan	officer: VP & CFO	620 LESHER PLACE, LANSING MI 48912
Jeffrey D Capello	director	C/O NEOGEN CORP., 620 LESHER PLACE, LANSING MI 48912
Aashima Gupta	director	C/O NEOGEN CORPORATION, 620 LESHER PLACE, LANSING MI 48912
John Edward Adent	officer: Chief Executive Officer	822 7TH STREET, SUITE 740, GREELEY CO 80631
Darci L Vetter	director	620 LESHER PLACE, LANSING MI 48912
Ronald D Green	director	620 LESHER PLACE, LANSING MI 48912
James C Borel	director	1007 MARKET STREET, WILMINGTON DE 19898
Terri A Morrical	officer: General Manager
G Bruce Papesh	director	726 APPLEGATE LANE, EAST LANSING MI 48823